Pfizer (NYSE:PFE) reported that its late stage lung cancer drug sigvotatug vedotin did not significantly improve overall ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Medically reviewed by Archana Sharma, DO NSCLC starts in the lungs, but when it metastasizes, it spreads to other body ...

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) ...

About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in ...

In this video, Lukas Delasos, DO, talks about recent study findings that showed nearly half of older adults diagnosed with ...

Pfizer Inc. PFE on Monday reported mixed topline results from its Phase 3 SigVie-002 trial of investigational antibody-drug ...

New research presented at the ASCO Annual Meeting 2026 demonstrates that biomarker-guided lung cancer treatment offers ...

A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 patients with small cell lung cancer and brain metastases, finding they ...

Pfizer said on Monday its drug for ​a type of lung cancer ‌missed the main goal of improving survival in patients compared to ...

Small cell lung cancer cells that metastasize to the brain cozy up to neurons and form working electrical connections, called synapses, according to a study led by Stanford Medicine researchers. The ...

Breast cancer (BC) is currently one of malignant and is estimated to account for 30% of all new cancer diagnosed in women. It is also the major cause of most cancer-related deaths, and metastasis of ...